• Family Conference 2023
  • DecNewsletter
  • First Legacy Guardian Peggy Davis


OUR MISSION

In our drive to find a cure for NBIA,
we provide support to families, educate the public and accelerate research with collaborators from around the world.


 

News

NBIAcure prepares to submit for FDA
approval of CoA-Z compound

 

Educational Resources

​Posters, flyers and
other educational handouts

 

Following is a list of medical terms that NBIA patients and their families may hear from their doctor, see written in medical reports or perhaps read in research articles about NBIA disorders.

We feel it is helpful to learn about these terms so that you have a better understanding of NBIA disorders. Please discuss any terminology you do not understand or would like more information about with your clinician if you believe it is relevant to caring for the NBIA individual.

We will continue to add to this list, so if you learn of a term that is not listed that you believe would be helpful, please send to info@NBIAdisorders.org.

 

aspiration pneumonia pneumonia caused by the drawing of a foreign substance, such as the gastric contents, into the bronchial tree during inhalation.

ataxic gait an unsteady, uncoordinated walk, employing a wide base and the feet thrown out.

athetosis repetitive involuntary, slow, sinuous, writhing motions, especially severe in the hands.

autonomic involvement what your body does automatically without conscious effort (heart beating, temperature regulation, breathing). Some NBIA individuals have problems involving these functions, such as temperature fluctuations, as their disease progresses.

autosomal recessive inheritance because most of our genes exist in pairs (one coming from the mother and one coming from the father), we normally carry two working copies of each gene. When one copy of a recessive gene has a change (mutation) in it, the person should still have normal health. That person is called a carrier. Recessive diseases only occur when both parents are carriers for the same condition and then pass their changed genes on to their child. Statistically, there is a one in four chance that two carriers would have an affected child, a two in four chance to have a child who is also a carrier, and a one in four chance to have a child who did not receive the gene mutation.

benzodiazepines (Valium, Librium, Xanax, Ativan) are a type of antianxiety drugs that help relieve nervousness, tension, and other symptoms by slowing the central nervous system. Some also help to control muscles spasms for NBIA individuals.

blepharospasm spasmodic blinking and closing of the eyelid caused by the involuntary contraction of the eyelid muscle.

botulinum toxin a neurotoxin made by Clostridium botulinum; causes paralysis in high doses, but is used medically in small, localized doses to treat disorders associated with involuntary muscle contraction and spasms, in addition to strabismus. Injected into muscles, it can cause temporary weakness of muscles that have involuntary contractions causing pain, twisting, abnormal posture, or changes in person’s voice or speech, relieving pain for a few months at a time.

bradykinesia extreme slowness in movement.

cerebellar atrophy general loss of brain cells and tissue in the cerebellar area of the brain.

cerebral atrophy general loss of brain cells and tissue in the cerebral area of the brain.

chorea the ceaseless occurrence of involuntary, rapid, jerky, involuntary movements.

choreoathetosis a condition characterized by involuntary, rapid, jerky movements (chorea) occurring in association with relatively slow, sinuous, writhing motions (athetosis).

corpus striatum a subcortical mass of gray and white substance in front of and lateral to the thalamus in each cerebral hemisphere.

corticospinal tract a tract of nerve cells that carries motor commands from the brain to the spinal cord.

de novo mutation (de novo means anew.) there is an alteration in a gene that is new in the affected individual and was not inherited from either parent. This can happen in a germ cell (egg or sperm) from one of the parents or in the fertilized egg itself.

deep brain stimulation (DBS) performed by implanting electrodes into the brain with a patient programmable device (neurostimulator) under the skin of the chest or abdomen. The neurostimulator sends pulses to targeted areas of the brain and takes “off line” the part of the brain that is sending too many signals and causing the muscles to move in painful ways as they do in dystonia.

dominant inheritance an individual has one working copy and one copy of the gene that has a change or mutation. This single mutation is enough to cause the disease. There is a one in two chance (50%) that an affected individual will pass the gene change on to any of his/her children. Most individuals with a dominant disorder have one parent who is also affected.

dopaminergic agents relating to, involved in, or initiated by the neurotransmitter activity of dopamine or related substances. Dopamine is a brain chemical called a neurotransmitter that carries signals between nerve cells and helps the brain perform critical functions. Dopamine helps the brain control motor functions and movement and possibly to perform other functions related to mood. An imbalance or shortage of dopamine can cause brain dysfunction and disease.

dysarthria a speech disorder caused by involuntary muscle cramping that affects the muscles in the mouth and throat causing poor articulation and slurring.

dyskinesias a movement disorder which consists of adverse effects, including diminished voluntary movements and the presence of involuntary movements. Dyskinesia can be anything from a slight tremor of the hands to uncontrollable movement of, most commonly, the upper body, but can also be seen in the lower extremities.

dysphagia involuntary muscle cramping that affects the muscles in the mouth and throat causing difficulty swallowing.

dystonia one of the dyskinesias. Dystonia is a neurological movement disorder in which involuntary sustained muscle cramping/contractions may force certain body parts into unusual, and sometimes painful, movements and positions. Dystonia may affect a single body area or be generalized throughout multiple muscle groups. Although there are several forms of dystonia and the symptoms may outwardly appear quite different, the element that all forms share is the repetitive, patterned, and often twisting involuntary muscle contractions.

dystonia-parkinsonism characterized by the abrupt onset of slowness of movement (parkinsonism) and dystonic symptoms.

dystonic storm continuous, unremitting, severe dystonic movements, either worsening on a background of dystonia or beginning anew. It can last at least hours to days, producing severe physical and psychological distress.

electroretinogram device that detects eye changes.

extensor toe signs indicate damage to the central nervous system. To a painful, pricking stimulus on the sole of the foot: (1) The healthy side shows flexion of thigh, leg, foot, and toes; (2) The paralyzed side shows flexion of thigh, leg, foot, but the toes extended.

eye of the tiger sign seen on an MRI caused by excess iron deposition in the globus pallidus. Almost always seen in Pantothenate Kinase-Associated Neurodegeneration (PKAN).

fat (lipid) metabolism lipids are absorbed from the intestine and undergo digestion and metabolism before they can be utilized by the body. Most of the dietary lipids are fats and complex molecules that the body needs to break down in order to utilize and derive energy from.

ferriprox brand name for the drug deferiprone, an oral drug that chelates iron, and is the focus of a clinical trial for PKAN to determine if it is helpful for NBIA disorders.

freezing  term used to describe movement that stops during ambulation, especially when turning corners or encountering surface variations.

gastrostomy tube medical device used to provide nutrition to patients who cannot obtain nutrition by mouth, are unable to swallow safely, or need nutritional supplementation. The state of being fed by a feeding tube is called gavage, enteral feeding or tube feeding.

gene mutations changes within a gene that may cause disease

global developmental delay Global Developmental Delay (GDD) is the general term used to describe a condition that occurs during the developmental period of a child between birth and 18 years. It is usually defined by the child being diagnosed with having a lower intellectual functioning than what is perceived as ‘normal’. It is usually accompanied by having significant limitations in communication. It is said to affect about 1-3% of the population.

globus pallidus  a structure in the brain involved in the regulation of voluntary movement. It is part of the basal ganglia, which, among many other things, regulate movements that occur on the subconscious level. If the globus pallidus is damaged, it can cause movement disorders, as its regulatory function will be impaired. When it comes to regulation of movement, the globus pallidus has a primarily inhibitory action that balances the excitatory action of the cerebellum. These two systems are designed to work in harmony with each other to allow people to move smoothly, with even, controlled movements. Imbalances can result in tremors, jerks, and other movement problems, as seen in some people with progressive neurological disorders characterized by symptoms like tremors and dystonia.

gonadal dysfunction or hypogonadism is the condition more prevalent in males in which the production of sex hormones and germ cells are inadequate.

hyperreflexia an exaggerated response of the deep tendon reflexes, usually resulting from injury to the central nervous system or metabolic disease. Also called autonomic dysreflexia.

hyperintense when an abnormality is bright (white) on MRI.

hypointense globus pallidus  radiographic evidence of increased amounts of iron in the globus pallidus. Hypointense (less intense): If an abnormality is dark on MRI, we describe it as hypointense.  

hypotonia floppy or low muscle tone (the amount of tension or resistance to stretch in a muscle), often involving reduced muscle strength.

intrathecal baclofen pump involves injecting the drug baclofen into the fluid-filled area surrounding the spinal cord. This area is called the intrathecal space. A programmable pump and catheter are surgically placed inside the body and deliver the baclofen continuously based on the settings deemed appropriate by your doctor.

iron chelation the administration of chelating agents to remove iron from the body. Since the 1970s, iron chelation therapy has been used to treat excess iron stores in the blood. The iron in NBIA is stored in the brain, so it requires a chelator that can cross the blood brain barrier to be effective, such as deferiprone.

lewy bodies abnormal aggregates of protein that develop inside nerve cells in the brain in Parkinson's disease (PD), Lewy body dementia and some other disorders, including NBIA.

lewy neurites abnormal clusters of protein that develop inside the nerve cells

muscular rigidity an alteration of muscle tone in which the muscles are in an involuntary state of continual tension. Muscle rigidity can be a manifestation of neurological damage (basal ganglia diseases) or a side effect of certain medications. Muscle rigidity is the continuous, tonic contraction of the skeletal muscles, often more marked in the flexor muscles than extensors.

neuropsychiatric mental disorder due to disease of the nervous system.

nyctalopia night blindness.

nystagmus  rapid involuntary eye movements.

occult bone fracture fracture without apparent trauma that may be caused by the combination of osteopenia in a non-ambulatory individual with marked stress on long bones from dystonia.

opisthotonos backward arching C from dystonia. The person is usually rigid and arches the back, with the head thrown backward. If a person with opisthotonos lies on his or her back, only the back of the head and the heels touch the supporting surface.

optic atrophy affects the optic nerve, which sends messages between the retina and the brain. When the nerve is damaged or breaks down, vision can become blurry, side vision or color vision may be abnormal, the pupil may not work properly, or there may be decreased lightness in one eye compared to the other. Eventually, optic atrophy can cause blindness.

osteopenia a condition where bone mineral density is lower than normal, with a T score between   -1.0 and -2.5

osteoporosis a progressive bone disease that's characterized by a decrease in bone mass and density and that leads to an increased risk of fracture. Osteoporosis is defined by the World Health Organization (WHO) as a bone mineral density of 2.5 standard deviations or more below the mean peak bone mass.

palilalia speech disorder characterized by the involuntary repetition of syllables, words, or phrases.

parkinsonism a neurological syndrome marked by tremor, slowness, rigidity and poor balance. The underlying causes of parkinsonism are numerous, and diagnosis can be complex. The neurodegenerative condition Parkinson's disease (PD) is the most common cause of parkinsonism but it is also seen in some of the NBIA disorders.

paroxysmal a fit, attack, or sudden increase or recurrence of symptoms (as of a disease).

phenotypes is the composite of an organism's observable characteristics or traits, such as its morphology, development, biochemical or physiological properties, phenology, behavior, and products of behavior. It is used when describing the traits of a disease.

pre-implantation genetic diagnosis (PGD) refers to genetic profiling of embryos prior to implantation.

psychomotor regression loss of previously acquired milestones.

retinitis pigmentosa an inherited, degenerative eye disease that causes severe vision impairment and sometimes blindness . It is common in the classic form of PKAN.

spasticity stiffness because of continuous resistance to muscle relaxing, Reflexes (for example, a knee-jerk reflex) are stronger or exaggerated. Spasticity is usually caused by damage to the part of the brain that is involved in movements under your control. It may also occur from damage to the nerves that go from the brain to the spinal cord. Severe, long-term spasticity may lead to contracture of muscles, which can reduce range of motion or leave the joints bent.

spheroids, spheroid bodies, or axonal spheroids nerve cells have long extensions, called axons that transmit messages from one nerve cell to the next. In NBIA, some axons are found to be swollen with collections of cellular debris or “junk” that should not be there.

strabismus crossed eyes.

substantia nigra a brain structure located in the mesencephalon (midbrain) that plays an important role in reward, addiction, and movement. Substantia nigra is Latin for "black substance", reflecting the fact that parts of the substantia nigra appear darker than neighboring areas due to high levels of melanin in dopaminergic neurons. Some NBIA individuals have iron deposits in this area.

systemic iron deficiency systemic denotes the part of the circulatory system concerned with the transportation of oxygen to and carbon dioxide from the body in general, esp. as distinct from the pulmonary part concerned with the transportation of oxygen from and carbon dioxide to the lungs. Systenic iron deficiency is low iron affecting the body generally.

tachylalia  extremely rapid speech.

torticollis a condition in which there are involuntary contractions of neck muscles resulting in abnormal movements and positions of the head and neck.

transdermal scopolamine patch a scopolamine patch placed on the skin behind the ear used to control excessive mouth secretions, drooling, nausea, and vomiting. Each patch is good for 3 days.

white matter changes in the brain changes in white matter known as amyloid plaques are associated with Alzheimer's disease and other neurodegenerative diseases. White matter injuries ("axonal shearing") may be reversible, while gray matter regeneration is less likely.

 

 

 

Dr. Tamara ZagustinManaging dystonia in NBIA patients:
A treating doctor’s perspective

- By Dr. Tamara Zagustin

One of the most common and disabling symptoms of NBIA is dystonia, a movement disorder that causes problems with walking, motor function, posture, speech, swallowing, pain and breathing. Sometimes, spasticity and exaggerated reflexes occur in conjunction with dystonia. Because the course of NBIA is unpredictable, managing dystonia is daunting.

In individuals with NBIA, dystonia is considered secondary dystonia and has different features than a primary dystonia diagnosis. This is important because managing secondary dystonia is very different than primary dystonia.

Primary dystonia is usually associated with a genetic inherited disorder that is progressive yet without other neurological symptoms such as seizures, retinal degeneration or loss of intellectual function. Usually, primary dystonia is more responsive to treatments than secondary dystonia with systemic therapies such as carbidopa-levodopa, deep brain stimulation (and botulinum toxin intramuscular injections. For the purposes of this article, we will be referring to the management of secondary dystonia in the presence of NBIA.

So far, many of the interventions that seem to improve NBIA symptoms, including dystonia, become diminished over time. Consequently, clinicians continue to work closely with families and patients to adjust treatments, with the goal of maintaining as high a quality of life as possible for patients.

The search continues for treatments that would:

  • Be successful in controlling dystonia and spasticity to improve motor function, care, comfort and quality of life.
  • Target the specific brain regions where dystonia symptoms originate.
  • Require the smallest effective dose with the least side effects.
  • Provide flexibility in managing the drug or treatment, while maintaining safety and consistency over time.
  • Allow individualization of the treatment.
  • Be reversible with no permanent changes.
  • Minimize invasiveness, side effects and complications.
  • Be universally available and affordable.
  • Be fit for use early in life so the disease could be treated aggressively from the start

Some of the medications for disabling dystonia with or without spasticity include baclofen, clonazepam, gabapentin, clonidine and trihexyphenidyl. Many times, more than one medication is needed to facilitate better management of dystonia’s involuntary movements, which can be very impairing and painful. Unfortunately, there is no perfect medication or intervention to address dystonia effectively. Moreover, side effects may crop up early on — before the drugs’ full potential can be seen.

Of note, medical cannabis has been reported to provide benefits to individuals with spasticity and dystonia by decreasing muscle spasms, neuropathic pain and/or alleviating gastrointestinal symptoms such as nausea and appetite loss.

To date, the FDA has not approved a marketing application for cannabis for the treatment of any disease or condition. There is one cannabis derived drug product cannabidiol (CBD) approved for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome and 2 synthetic type cannabis related drug products: dronabinol and nabilone which are indicated for nausea associated with cancer chemotherapy. None of these FDA products are indicated for hypertonia or neuropathic pain.

Any other cannabis product available is not FDA approved and therefore cannot have a medical prescription as the ingredients are unknown and uncertain. Medical insurance will not cover these other cannabis derived products as they are considered experimental, and state laws allowing medical cannabis vary. Potential side effects and interactions with other medications must be considered when using these products.

Any form of medical cannabis that has more than low amounts of THC, the psychoactive component of cannabis, can negatively affect a child’s neurodevelopment. However, optimal management of spasticity and neuropathic pain requires a higher ratio of THC to CBD than the typical low THC-high CBD therapy calls for. Those are important considerations when discussing medical cannabis as an intervention for dystonia in individuals younger than 21.

When dystonia symptoms are localized to specific muscles, it is reasonable to consider targeted intramuscular botulinum toxin injections. When more muscles are affected and/or the amount of botulinum toxin is limited by the child’s low body weight, a combination of botox and phenol (6%) or ethanol (60 to 70%) nerve injections could be considered — with or without systemic medications (oral medications or intrathecal therapy).

When oral baclofen is no longer effective, intrathecal baclofen therapy could be considered, probably earlier rather than later to obtain the most benefit. That involves the surgical implantation of a drug delivery device (a programmable pump with a catheter). The device delivers baclofen into the fluid-filled area surrounding the spinal cord and brain (cerebral spinal fluid), an area called the intrathecal space. Settings on the pump deliver baclofen continuously based on the doctor’s prescribed amount. The intrathecal baclofen therapy is not without risks, such as infection, baclofen withdrawal or overdosing.

On the plus side, intrathecal baclofen therapy is more effective than oral baclofen and at a much lower dosage (80 to 100 times less). The treatment is reversible at any time by removing the device, and there is flexibility in how the dosage is delivered by using a continuous or flexible mode or a combination of modes together. The intrathecal baclofen therapy is invasive and should be considered when conservative management of dystonia with oral medications, localized injections, orthotics, therapies and other interventions fail to address treatment goals.

To optimize intrathecal baclofen therapy for dystonia management, here are some tips for clinicians:

  • Consider initially an intrathecal baclofen trial (via lumbar puncture or via an external intrathecal catheter) to see if there is any benefit before committing to surgery and ongoing management of the therapy.
  • Consider the placement of the drug delivery device with the largest available reservoir for the intrathecal baclofen as the doses are usually elevated over time to manage dystonia. This would minimize the frequency of medical visits needed for the drug delivery device to be refilled within a timely fashion to prevent complications from withdrawal, which would happen if the device runs out of medication.
  • The catheter tip should be placed as close as possible to the brain, the target for dystonia. The tip can either go up high in the cervical region or within the brain itself. Devices on the market are approved for intrathecal use, yet studies show that using them in the intraventricular region has the same rate of morbidity/mortality as using in the intrathecal space.
  • Work with an experienced team of professionals, including neurosurgeons, neurologist, physiatrist and others on the rehabilitation team with expertise in movement disorders and experience with intrathecal baclofen therapy.
  • Patients should make regular visits to the doctor after the drug delivery device is first implanted, at least once every week or two, to optimize baclofen therapy dose within the first three months. Dosage should be increased in a progressive but conservative way. Usually, the dose for dystonia management is much higher than the dose for spasticity. The upper limit is usually determined by the best response with minimal side effects. Many times, additional systemic medications already in place for dystonia, such as clonidine, gabapentin, clonazepam, trihexyphenidyl, must be continued.
  • Consider implementing intrathecal baclofen with a flex mode in which boluses are programmed every three hours at relatively high dosages (which could be as high as 200 mcg per bolus) in addition to a basal rate (continuous mode).
  • Treating physicians should maintain good communication with patients in case of complications. Withdrawal is probably more common than overdose given the possibility of an acute pump malfunction with an intrathecal baclofen dosage that is usually greater than 2,000 mcg/day).
  • At each visit continue to re-evaluate the effectiveness of the treatment and the need for adjustments of the intrathecal baclofen therapy to optimize this intervention, especially given NBIA’s unpredictability, variability and progressive nature. This makes the therapy challenging for even the most experienced clinician.
  • Be goal-oriented with all interventions. The goals can evolve throughout the different stages of the disease. Be realistic and recognize the limits of what can be achieved over time with the complexity of NBIA. Be objective, compassionate and thoughtful.
  • Other therapies such as oral medications, botulinum toxin intramuscular injections, phenol/ethanol neural injections and deep brain stimulation can and should be used when appropriate in conjunction with intrathecal baclofen therapy to maximize outcomes and results.

More studies are needed on optimal management of secondary dystonia to improve our understanding of how to control it better and facilitate appropriate neurodevelopmental skills, maintain function with independence in activities of daily living, cost-effectiveness, care, comfort and quality of life for affected individuals with NBIA and their caregivers.

Feel free to contact me if there are any questions, comments or other at tkzagustin@hotmail.com

Tamara Zagustin, M.D. is board-certified in Physical Medicine and Rehabilitation, Brain Injury Medicine and Pediatric Rehabilitation Medicine. She earned her medical degree from the Universidad Central de Venezuela (1991) and completed her Physical Medicine and Rehabilitation residency both at the Universidad Central de Venezuela (1996) and at the University of Arkansas for Medical Sciences (2007). She completed a fellowship in Pediatric Rehabilitation Medicine at the Children’s Hospital in Denver, University of Colorado (December 2008) and later joined Rady Children’s Hospital San Diego in January 2009 - September 2010. Now she is practicing at Kapiolani Medical Center for Women and Children, Honolulu, Hawaii. She has great interest in the health of children and adults with chronic disabling neurological diseases such as cerebral palsy, neurodegenerative diseases, spinal cord injury, movement disorders, brain injury, palliative care in children with complex neurological disorders and chronic pain syndromes.

Dr. Zagustin has participated in NBIA clinical appointments family conferences since 2011, giving her valuable experience with NBIA individuals. She was the treating physician for NBIA Disorders Association President Patricia Wood's daughter Kimberly when she received her intrathecal baclofen pump in 2010.

Iron Chelation Clinical Trials

All NBIA disorders share iron accumulation in the globus pallidus structure of the brain. It remains unclear, however, whether excess iron causes NBIA or is brought on by some other problem. Iron chelating drugs were thought to be a potential NBIA therapy by removing excess iron from the brain.

Iron chelating agents have been tried without clear benefit. Initially, trials were limited by the development of systemic iron deficiency before any clinical neurologic benefits were evident.

A long-term deferiprone (iron chelator) study with 88 participants with Pantothenate Kinase-Associated Neurodegeneration (PKAN) was done from December 2012 to April 2015 through an international trial conducted at clinical centers in the US, Germany, Italy and the United States under a 5.2 million euros (approximately 7 million USD) EU grant called Treat Iron-Related Childhood-Onset Neurodegeneration, or TIRCON. Unlike earlier drugs, deferiprone crosses the blood-brain barrier and removes intracellular iron. There was also an open label extension study for an additional 18 months which completed in 2018 where the drug was made available to everyone who took part in the trial.

The study was a gold standard study: randomized, double-blind and placebo-controlled. “Placebo-controlled” means that in the context of the study, deferiprone was compared with a placebo. A placebo looks identical to the deferiprone but does not contain any active ingredient.

This study showed that while the drug successfully reduced the amount of accumulated iron in the brain for PKAN individuals regardless of onset age, the treatment was not effective for PKAN patients in a statistically significant way. The study found a slight indication that deferiprone may slow the progression of the disorder in older patients with later-onset, or atypical PKAN.

The lead investigator of the trial in the United States, Dr. Elliot Vichinsky of the University of California, San Francisco Benioff Children’s Hospital in Oakland, said that older and younger PKAN individuals showed improvement with deferiprone in dystonia of the lower face and lower legs, as well as in cognitive functioning, especially memory. But the benefit in younger children, who tend to have a faster-moving, more severe form of PKAN was less than that of older adults with a later onset of disease, and neither was statistically significant.

Vichinsky said, "The drug was well-tolerated, and the safety profile was very good."

But because the study did not meet a key goal - showing a statistically important improvement from deferiprone in all age groups – the U.S. Food and Drug Administration has not approved it for use in PKAN.

Published papers on this work:

2019 - Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study

Deep brain stimulation (DBS) is another option used to treat dystonia in NBIA individuals, most often in those with PKAN. It involves placing electrodes in the brain. They are attached to wires leading to a battery-operated neurostimulator implanted in the chest. The neurostimulator sends pulses to targeted areas in the brain and takes “off line” the part of the brain that is sending too many signals and causing the muscles to move in painful ways as they do in dystonia.

DBS is not without risks, although extremely rare in well-trained centers. The most severe is bleeding in the brain. Other surgery risks include infections, seizures and an allergic reaction to implanted materials. Side effects of the surgery may include increased dystonia and speech problems like whispering (dysarthria) and trouble forming words (dysphasia), which are usually reversible. However, the total number of severe complications are in the range of 1 percent to 2 percent. Therefore, the risks are considered acceptable in patients expected to have a good or very good operation outcome.

Because a limited number of persons with NBIA have undergone such treatment and care has been provided at a variety of centers, it is not possible to evaluate the efficacy of DBS for this population at this time. Even with these limitations, studies suggest DBS may hold promise. Larger prospective studies may improve understanding of the factors that influence the outcomes of DBS use in NBIA.

 

 

Partners

nbia alliance logo1NBIA Cure logoRare Disease Day PartnerTIRCON

Genetic Alliance logoNORDEURORDISGlobal Genes


Disclaimer    |     Privacy Policy    |     Financials    |     Contact Us

Give While You Shop!

Igive.com

G-CFB5FV5NLL